Related Experiment Video
Updated: Aug 15, 2026
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Drug effects on CA125 antigen expression and antibody binding to cancer cells
1Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.
Abstract:
CA125 is a high-molecular weight glycoprotein expressed on most serous-type ovarian cancer and some lung adenocarcinoma tissues. The effects of various drugs on the release of CA125 antigen into culture medium and on monoclonal antibody (MAb) binding to cancer cells were studied using 8 human cancer cell lines, all of which expressed CA125 on their cell surfaces. The effect of dexamethasone was seen at as low a concentration as 10(-9) M dexamethasone, and the release of CA125 and the binding of radiolabelled anti-CA125 antibody were completely inhibited after exposure to 10(-7) M dexamethasone. The number of antibody binding sites markedly decreased. In contrast, sodium butyrate increased CA125 expression. These findings were clearly detected in only 3 cancer cell lines and a significant effect was not seen in the 5 other cancer cell lines. Interferon-gamma, examined in 3 cell lines, suppressed in a dose-dependent manner in 2 CA125 expression cell lines, but enhanced it in one line. No apparent effects were seen after exposure to tissue necrosis factor or interleukin-2. These results suggest that drugs may regulate the CA125 antigen expression in some, but not all, cancer cells and may affect the biodistribution of radiolabelled MAbs.
Insights
Dexamethasone inhibited cancer antigen CA125 release and antibody binding, while sodium butyrate increased it in some cell lines. Drug effects on CA125 (cancer antigen 125) expression vary across cancer types.
Area of Science:
- Oncology
- Biochemistry
- Immunology
Background:
- CA125 (cancer antigen 125) is a glycoprotein found on ovarian cancer and lung adenocarcinoma.
- Understanding CA125 regulation is crucial for cancer diagnostics and therapeutics.
- Monoclonal antibodies (MAbs) targeting CA125 are used in imaging and therapy.
Purpose of the Study:
- To investigate the effects of various drugs on CA125 antigen expression and MAb binding.
- To determine if drug-induced changes in CA125 affect MAb biodistribution.
- To identify potential therapeutic strategies modulating CA125 levels.
Main Methods:
- Utilized 8 human cancer cell lines expressing CA125.
- Assessed CA125 release and MAb binding after drug treatment (dexamethasone, sodium butyrate, interferon-gamma, TNF, IL-2).
- Quantified changes in CA125 levels and antibody binding site density.
Main Results:
- Dexamethasone (10(-7) M) completely inhibited CA125 release and MAb binding in sensitive cell lines.
- Sodium butyrate increased CA125 expression in 3 of 8 cell lines.
- Interferon-gamma showed variable effects, suppressing or enhancing CA125 expression depending on the cell line.
Conclusions:
- Drugs can differentially regulate CA125 antigen expression in a subset of cancer cells.
- Modulation of CA125 by drugs may impact the efficacy of radiolabeled MAb-based therapies.
- Further research is needed to explore drug-specific effects on CA125 for targeted cancer treatment.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
05:21Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
Published on: September 13, 2024
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy